Eli Lilly and Company (NYSE: LLY) Q2 2022 earnings call dated Aug. 04, 2022 Corporate Participants: Kevin Hern -- Vice President of Investor Relations
Eli Lilly and Company
-(LLY)
Get the latest Eli Lilly and Company (LLY) stock news, earnings analysis, earnings conference calls, earnings transcripts from AlphaStreet.
Eli Lilly and Company (LLY) Earnings: 2Q22 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported second quarter 2022 earnings results today. Worldwide revenue decreased 4% to $6.49 billion compared to the
Stock Watch: Should you invest in Eli Lilly (LLY) after Q1 earnings?
For Eli Lilly and Company (NYSE: LLY), 2021 was a fruitful year in terms of financial performance and product development. Reflecting the
Earnings: Highlights of Eli Lilly’s (LLY) Q1 2022 results
Eli Lilly and Company (NYSE: LLY) has reported higher earnings and revenues for the first quarter of 2022. The numbers also surpassed
Eli Lilly and Company (LLY) Q1 2022 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2022 earnings call dated Apr. 28, 2022 Corporate Participants: Kevin Hern -- Vice President of Investor Relations
Eli Lilly and Company (LLY) Q4 2021 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Kevin Hern — Investor Relations David A. Ricks — Chair
Eli Lilly and Company (LLY) Earnings: 4Q21 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported revenue of $7.9 billion for the fourth quarter of 2021, up 8% year-over-year. Reported net
Eli Lilly and Company (LLY) Earnings: 3Q21 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported revenue of $6.7 billion for the third quarter of 2021, up 18% year-over-year. Reported net
Eli Lilly and Company (LLY) Q3 2021 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q3 2021 earnings call dated Oct. 26, 2021 Corporate Participants: Kevin Hern -- Vice President of Investor Relations
Eli Lilly and Company (LLY) Q2 2021 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q2 2021 earnings call dated Aug. 03, 2021 Corporate Participants: Kevin Hern -- Investor Relations David A. Ricks -- Chairman
Earnings calendar for the week of August 2
Labor market conditions improved once again and jobless claims dropped to about 400,000 after rising last week, as economic activity picked up.
LLY Stock: Is Eli Lilly a good bet in COVID-challenged healthcare market?
For pharmaceutical companies, 2020 was a busy year when the healthcare sector went into overdrive to deal with the challenges posed by
Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript
Eli Lilly and Company (NYSE: LLY) Q1 2021 earnings call dated Apr. 27, 2021 Corporate Participants: Kevin Hern -- Vice President, Investor Relations David A.
Earnings calendar for the week of April 26
Investor sentiment was hit by the government's proposal to levy higher capital gain tax on wealthy individuals, and the market shifted to
Eli Lilly & Co (LLY) Q4 2020 Earnings Call
Eli Lilly & Co (NYSE: LLY) Q4 2020 earnings call dated Jan. 29, 2021 Corporate Participants: Kevin Hern — Vice President of Investor Relations David
Where do these companies stand in the COVID-19 vaccine race?
After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the
Eli Lilly & Co (LLY) Q4 2020 Earnings Call Transcript
Eli Lilly & Co (NYSE: LLY) Q4 2020 earnings call dated Jan. 29, 2021 Corporate Participants: Kevin Hern -- Vice President of Investor Relations
Earnings calendar for the week of January 25
Leading stock indices continued the recent rally this week, with S&P 500 and Dow Jones Industrial Average setting new records helped mainly
Latest study shows Eli Lilly’s (LLY) antibody reduces COVID-19 by 80%
Eli Lilly and Company (NYSE: LLY) announced that the results from its latest study indicated that its monoclonal antibody bamlanivimab reduced the
Eli Lilly (LLY) is paving the way to a strong 2021
Shares of Eli Lilly & Co. (NYSE: LLY) were up over 2% on Wednesday. The stock has gained over 30% since the
COVID-19 vaccine: These pharma companies have also made headway
The month of November has been huge for pharmaceutical companies with many submitting positive results from their clinical trials for the development